Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C25H25O6.Na |
| Molecular Weight | 444.4522 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].CO[C@@H](CC1=CC=C(OCCCOC2=CC=C(OC3=CC=CC=C3)C=C2)C=C1)C([O-])=O
InChI
InChIKey=QRZVPGNFLXIZON-JIDHJSLPSA-M
InChI=1S/C25H26O6.Na/c1-28-24(25(26)27)18-19-8-10-20(11-9-19)29-16-5-17-30-21-12-14-23(15-13-21)31-22-6-3-2-4-7-22;/h2-4,6-15,24H,5,16-18H2,1H3,(H,26,27);/q;+1/p-1/t24-;/m0./s1
| Molecular Formula | C25H25O6 |
| Molecular Weight | 421.4624 |
| Charge | -1 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
| Molecular Formula | Na |
| Molecular Weight | 22.9898 |
| Charge | 1 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Naveglitazar is an oral dual peroxisome proliferator-activated receptor (PPAR) agonist, which was under development with Ligand Pharmaceuticals for the treatment of type 2 diabetes mellitus. Naveglitazar is a nonthiozolidinedione peroxisome proliferator-activated receptor (PPAR) α-γ dual, γ-dominant agonist that has shown glucose-lowering potential in animal models and in the clinic. Naveglitazar had been in phase II clinical trials for the once-daily oral treatment of type 2 diabetes, however, the development was discontinued.
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| The disposition and metabolism of naveglitazar, a peroxisome proliferator-activated receptor alpha-gamma dual, gamma-dominant agonist in mice, rats, and monkeys. | 2007 Jan |
|
| Rat Urinary Bladder Carcinogenesis by Dual-Acting PPARalpha + gamma Agonists. | 2008 |
|
| Cross-Species Differential Plasma Protein Binding of MBX-102/JNJ39659100: A Novel PPAR-gamma Agonist. | 2008 |
|
| Urothelial carcinogenesis in the urinary bladder of rats treated with naveglitazar, a gamma-dominant PPAR alpha/gamma agonist: lack of evidence for urolithiasis as an inciting event. | 2008 Feb |
|
| Allometric prediction of the human pharmacokinetic parameters for naveglitazar. | 2008 Jul-Sep |
|
| Neoplastic and non-neoplastic changes in F-344 rats treated with Naveglitazar, a gamma-dominant PPAR alpha/gamma agonist. | 2009 Oct |
Sample Use Guides
The carcinogenic potential of naveglitazar, a gamma-dominant peroxisome proliferator-activated receptor (PPAR) alpha/gamma dual agonist, was evaluated in a two-year study in F344 rats (0, 0.3, 1.0, or 3.0 mg/kg, males; 0, 0.1, 0.3, or 1.0 mg/kg, females). Rats were randomly assigned to treatment groups based on
weight. Rats (60/sex/group) were assigned to groups receiving
0, 0.3, 1.0, or 3.0 mg naveglitazar/kg body weight/day (males)
or 0, 0.1, 0.3, or 1.0 mg naveglitazar/kg body weight/day
(females) by oral gavage.
Route of Administration:
Oral
| Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:25:41 GMT 2023
by
admin
on
Fri Dec 15 15:25:41 GMT 2023
|
| Record UNII |
9EPC7SXH23
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
477981-15-0
Created by
admin on Fri Dec 15 15:25:41 GMT 2023 , Edited by admin on Fri Dec 15 15:25:41 GMT 2023
|
PRIMARY | |||
|
58822574
Created by
admin on Fri Dec 15 15:25:41 GMT 2023 , Edited by admin on Fri Dec 15 15:25:41 GMT 2023
|
PRIMARY | |||
|
9EPC7SXH23
Created by
admin on Fri Dec 15 15:25:41 GMT 2023 , Edited by admin on Fri Dec 15 15:25:41 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
